End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.41 CNY | -3.20% | +1.96% | -19.39% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.39% | 1.86B | - | ||
-2.61% | 89.08B | A- | ||
+3.55% | 40.9B | A- | ||
-14.40% | 32.25B | B- | ||
+55.89% | 25.14B | A | ||
-15.96% | 15.39B | C | ||
-15.50% | 11.91B | B- | ||
-41.29% | 11.89B | B | ||
-11.75% | 11.64B | D+ | ||
+7.87% | 9.03B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301207 Stock
- Ratings Hualan Biological Vaccine Inc.